Dietary amelioration of Helicobacter pylori infection: Design criteria for a clinical trial

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 10, 2004, Pages 1610-1616

  Fahey, Jed W ^a,b   Muñoz, Alvaro ^b   Matsuzaki, Yasushi ^c   Suzuki, Hideo ^c   Talalay, Paul ^a,b   Tauchi, Masafumi ^c   Zhang, Songhua ^c   Hurt, Christopher ^a   Yanaka, Akinori ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; UREASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LONGITUDINAL STUDY; MALE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; STOMACH CANCER; TREATMENT OUTCOME; UREA BREATH TEST; URINALYSIS; VEGETABLE;

ADULT; AGED; BIOLOGICAL MARKERS; BRASSICACEAE; BREATH TESTS; CLINICAL TRIALS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; VEGETABLES;

EID: 4944238194     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. IARC. Globocan 2000: cancer incidence, mortality and prevalence worldwide. Version 1.0. Cancer Base No. 5. Lyon: IARC Press; 2001.
2. Pisani P, Parkin DM, Muñoz N, Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997;6:387-400.
3. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
4. Fahey JW, Haristoy X, Dolan PM, et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci U S A 2002;99:7610-5.
5. Haristoy X, Angoi-Duprez K, Duprez A, Lozniewski A. Efficacy of sulforaphane in eradicating Helicobacter pylori in human gastric xenografts implanted in nude mice. Antimicrob Agents Chemother 2003;47:3982-4.
6. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacler pylori therapy. J Natl Cancer Inst 2000;92:1881-8.
7. Turner NJ, Thomson BM, Shaw IC. Bioactive isoflavones in functional foods: the importance of gut microflora on bioavailability. Nutr Rev 2003;61:204-13.
8. Labenz J, Stolte M, Aygen S, Hennemann O, Bertrams J, Borsch G. Qualitative and semiquantitative invasive and noninvasive diagnosis of Helicobacter pylori colonization of gastric mucosa. Z Gastroenterol 1993;31:437-43.
9. 13C-urea breath test for diagnosis of Helicobacter pylori infection and estimation of the severity of gastritis. Digestion 1996;57:391-7.
10. 13C-Urea breath test to quantify H. pylori colonization of gastric mucosa an association with severity of inflammation. Gastroenterology 1994;106:A48.
11. 13C-urea breath test for identification of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1997; 9:1085-9.
12. 13C-urea breath test as a predictor of intragastric bacterial load and severity of Helicobacter pylon gastritis. Scand J Clin Lab Invest 1998;58:19-27.
13. 13C-urea breath test detection of Helicobacter pylori and its correlation with endoscopic and histologic findings. J Physiol Pharmacol 1996;47:79-90.
14. 13C urea breath test in Japanese patients. Helicobacter 2000;5:98-103.
15. Kobayashi D, Eishi Y, Ohkusa T, et al. Gastric mucosal density of Helicobacter pylori estimated by real-time PCR compared with results of urea breath test and histological grading. J Med Microbiol 2002;51: 305-11.
16. 13C-urea breath test: the impact of pH and gastric emptying. Aliment Pharmacol Ther 1999;13:1057-62.
17. 13C-urea breath test. Lancet 1987;1: 1174-7.
18. 13C-urea breath test. Nippon Rinsho 2001;59:267-71.
19. 13C breath tests: visions and realities. J Nutr 2001;131: S1637-42.
20. 13C urea breath test in the diagnosis of Helicobacter pylori infection. Gut 1999;45 Suppl 1:118-22.
21. Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P. Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. Cancer Epidemiol Biomarkers Prev 1998;7:1091-100.
22. Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P. Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and excretion in humans. Cancer Epidemiol Biomarkers Prev 2001;10:501-8.
23. Ye L, Dinkova-Kostova AT, Wade KL, Zhang Y, Shapiro TA, Talalay P. Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin Chim Acta 2002;316:43-53.
24. Zhang Y, Cho CG, Posner GH, Talalay P. Spectroscopic quantitation of organic isothiocyanates by cyclocondensation with vicinal dithiols. Anal Biochem 1992;205:100-7.
25. Zhang Y, Wade KL, Prestera T, Talalay P. Quantitative determination of isothiocyanates, dithiocarbamates, carbon disulfide, and related thiocarbonyl compounds by cyclocondensation with 1,2-benzene-dithiol. Anal Biochem 1996;239:160-7.
26. Blaser MJ, Berg DE. Helicobacter pylori genetic diversity and risk of human disease. J Clin Invest 2001;107:767-73.
27. Nir Y, Potasman I, Stermer E, Tabak M, Neeman I. Controlled trial of the effect of cinnamon extract on Helicobacter pylori. Helicobacter 2000;5:94-7.
28. McNulty CA, Wilson MP, Havinga W, Johnston B, O'Gara EA, Maslin DJ. A pilot study to determine the effectiveness of garlic oil capsules in the treatment of dyspeptic patients with Helicobacter pylori. Helicobacter 2001;6:249-53.
29. Opekun AR, Opekun JL, Graham DY. Broccoli (sulforaphane glucosinolate) for the treatment of H. pylori infection in humans [abstract]. Am J Gastroenterol 2003:M1502.
30. Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA 1994;272: 122-4.
31. Vickers AJ. Underpowering in randomized trials reporting a sample size calculation. J Clin Epidemiol 2003;56:717-20.
32. Browne RH. On the use of a pilot sample for sample size determination. Stat Med 1995;14:1933-40.
33. Guttner Y, Windsor HM, Viiala CH, Marshall BJ. Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:125-9.
34. Cruchet S, Obregon MC, Salazar G, Diaz E, Gotteland M. Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization in children. Nutrition 2003;19: 716-21.
35. Sakamoto I, Igarashi M, Kimura K, et al. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother 2001;47:709-10.
36. Cats A, Kuipers EJ, Bosschaert MA, Pot RG, Vandenbroucke-Grauls CM, Kusters JG. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther 2003;17:429-35.
37. 13Carbon urea breath test for Helicobacter pylori: comparison with histology, culture, and ELISA serology. Gut 1991;32:1461-4.
38. 13C-urea breath test for the detection of Helicobacter pylori. Eur J Gastroenterol Hepatol 1991;3:915-21.
39. 13C-urea breath test in Taiwan. J Gastroenterol 1998;33:330-5.